David Chiron

1.7k total citations
50 papers, 1.2k citations indexed

About

David Chiron is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, David Chiron has authored 50 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pathology and Forensic Medicine, 19 papers in Genetics and 19 papers in Oncology. Recurrent topics in David Chiron's work include Lymphoma Diagnosis and Treatment (26 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Multiple Myeloma Research and Treatments (7 papers). David Chiron is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Multiple Myeloma Research and Treatments (7 papers). David Chiron collaborates with scholars based in France, United States and United Kingdom. David Chiron's co-authors include Catherine Pellat‐Deceunynck, Martine Amiot, Steven Le Gouill, Gaëtan Jégo, Régis Bataille, Philippe Moreau, Benoît Tessoulin, Selina Chen‐Kiang, Patricia Gomez‐Bougie and Cyrille Touzeau and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

David Chiron

48 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Chiron France 20 500 454 442 433 353 50 1.2k
Georgios Z. Rassidakis United States 17 375 0.8× 489 1.1× 414 0.9× 207 0.5× 234 0.7× 34 1.0k
Barbara MacGregor‐Cortelli United States 10 500 1.0× 605 1.3× 424 1.0× 248 0.6× 198 0.6× 12 1.1k
Marzia Palma Sweden 18 244 0.5× 292 0.6× 521 1.2× 366 0.8× 549 1.6× 49 1.1k
James A. L. Fenton United Kingdom 16 693 1.4× 522 1.1× 320 0.7× 695 1.6× 486 1.4× 31 1.4k
Siddha Kasar United States 14 351 0.7× 448 1.0× 170 0.4× 522 1.2× 342 1.0× 34 1.0k
Samuli Eldfors Finland 16 273 0.5× 403 0.9× 239 0.5× 252 0.6× 255 0.7× 41 1.0k
Sophie Gazzo France 16 453 0.9× 266 0.6× 247 0.6× 448 1.0× 121 0.3× 32 856
Andrea G.S. Buggins United Kingdom 19 253 0.5× 332 0.7× 251 0.6× 474 1.1× 628 1.8× 33 1.1k
Virginia Kelly United States 16 316 0.6× 322 0.7× 394 0.9× 624 1.4× 232 0.7× 34 1.2k
John H. Proffitt United States 15 447 0.9× 444 1.0× 204 0.5× 438 1.0× 191 0.5× 17 1.1k

Countries citing papers authored by David Chiron

Since Specialization
Citations

This map shows the geographic impact of David Chiron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Chiron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Chiron more than expected).

Fields of papers citing papers by David Chiron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Chiron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Chiron. The network helps show where David Chiron may publish in the future.

Co-authorship network of co-authors of David Chiron

This figure shows the co-authorship network connecting the top 25 collaborators of David Chiron. A scholar is included among the top collaborators of David Chiron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Chiron. David Chiron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maïga, Sophie, Christelle Dousset, Agnès Moreau‐Aubry, et al.. (2025). VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target. Leukemia. 39(4). 995–1000.
2.
Chiron, David, François Guillonneau, Lucas Treps, et al.. (2025). MCL-1 as a molecular switch between myofibroblastic and pro-angiogenic features of breast cancer-associated fibroblasts. Cell Death and Disease. 16(1). 603–603. 1 indexed citations
3.
Bellanger, Céline, Benoît Tessoulin, Christelle Dousset, et al.. (2024). Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma. Haematologica. 109(8). 2574–2584. 1 indexed citations
4.
Bellanger, Céline, Yannick Le Bris, Juliana C. Santos, et al.. (2023). CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma. Blood. 142(18). 1543–1555. 11 indexed citations
5.
Descamps, Géraldine, Céline Bellanger, Christelle Dousset, et al.. (2023). A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics. Blood. 143(13). 1242–1258. 7 indexed citations
6.
Gouill, Steven Le, Franck Morschhauser, David Chiron, et al.. (2023). P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.. HemaSphere. 7(S3). e6048802–e6048802. 1 indexed citations
7.
Gouill, Steven Le, David Chiron, Krimo Bouabdallah, et al.. (2023). Long term follow‐up of untreated/relapsing MCL patients with the Ibrutinib, obinutuzumab, and venetoclax combination. Hematological Oncology. 41(S2). 478–479. 2 indexed citations
8.
Saleh, Khalil, Morgane Cheminant, David Chiron, et al.. (2022). Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma. Cancers. 14(13). 3229–3229. 15 indexed citations
9.
Gouill, Steven Le, Franck Morschhauser, David Chiron, et al.. (2020). Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 137(7). 877–887. 75 indexed citations
10.
André‐Grégoire, Gwennan, Magalie Feyeux, Philippe Hulin, et al.. (2019). Pannexin‐1 limits the production of proinflammatory cytokines during necroptosis. EMBO Reports. 20(10). e47840–e47840. 28 indexed citations
11.
Tessoulin, Benoît, Céline Bellanger, Philippe Moreau, et al.. (2019). CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia. 33(10). 2442–2453. 53 indexed citations
12.
Tessoulin, Benoît, Agnès Moreau‐Aubry, Géraldine Descamps, et al.. (2018). Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. Journal of Hematology & Oncology. 11(1). 137–137. 35 indexed citations
13.
Descamps, Géraldine, Sophie Maïga, Benoît Tessoulin, et al.. (2017). Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells. International Journal of Molecular Sciences. 19(1). 40–40. 3 indexed citations
14.
15.
Chiron, David, Maurizio Di Liberto, Peter Martin, et al.. (2014). Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma. Cancer Discovery. 4(9). 1022–1035. 204 indexed citations
16.
Chiron, David, Sophie Maïga, Sylvanie Surget, et al.. (2013). Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. Blood Cancer Journal. 3(6). e120–e120. 24 indexed citations
17.
Chiron, David, Peter Martin, Maurizio Di Liberto, et al.. (2013). Induction of prolonged early G1arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle. 12(12). 1892–1900. 59 indexed citations
18.
Surget, Sylvanie, David Chiron, Patricia Gomez‐Bougie, et al.. (2012). Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells. Cancer Research. 72(17). 4562–4573. 58 indexed citations
19.
Chiron, David, Sophie Maïga, Géraldine Descamps, et al.. (2012). Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Molecules and Diseases. 48(4). 247–253. 22 indexed citations
20.
Chiron, David, et al.. (2011). TLR9 Ligand Induces the Generation of CD20+ Plasmablasts and Plasma Cells from CD27+ Memory B-Cells. SHILAP Revista de lepidopterología. 2. 83–83. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Georgios Z. Rassidakis Breakdown of academic impact, for papers by Barbara MacGregor‐Cortelli Breakdown of academic impact, for papers by Marzia Palma Breakdown of academic impact, for papers by James A. L. Fenton Breakdown of academic impact, for papers by Siddha Kasar Breakdown of academic impact, for papers by Samuli Eldfors Breakdown of academic impact, for papers by Sophie Gazzo Breakdown of academic impact, for papers by Andrea G.S. Buggins Breakdown of academic impact, for papers by Virginia Kelly Breakdown of academic impact, for papers by John H. Proffitt
Rankless by CCL
2026